These observations outline possible clinical applications for LOX-1, as a prognostic factor in acute coronary syndrome [69] and as a potential pharmacological target, with a report describing reduced vascular toxicity induced by CRP and LOX-1 following treatment with atorvastatin [70]. Here, CRP is linked to acute coronary syndrome.